Furthermore, subgroup survival analysis at stage I showed the group with high NTF4 expression to have poorer PFS (p<0.05), suggesting that the upregulation of NTF4 in early breast cancer patients may serve as a predictive biomarker for progression or metastasis (Fig. 1E). This evidence concerns the gene NTF4 and breast cancer.